» Articles » PMID: 22154797

Expanding the Indications for Septal Myectomy in Patients with Hypertrophic Cardiomyopathy: Results of Operation in Patients with Latent Obstruction

Overview
Date 2011 Dec 14
PMID 22154797
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Many patients with symptomatic hypertrophic cardiomyopathy have minimal left ventricular outflow tract gradients, and there is uncertainty whether their limitation is due to diastolic dysfunction or labile outflow tract obstruction. The purpose of this study was to characterize the clinical presentation and outcome of septal myectomy in patients with hypertrophic cardiomyopathy and latent obstruction.

Methods: Among 749 patients who underwent septal myectomy, 249 had latent obstruction with minimal (0-30 mm Hg) resting gradients preoperatively. All were symptomatic and had more severe left ventricular outflow tract obstruction provoked by Valsalva maneuver or amyl nitrite inhalation during Doppler echocardiography or by stimulation with isoproterenol during catheterization. Clinical characteristics, survival, and functional outcome of these patients were compared with those of 500 patients with more severe resting left ventricular outflow tract obstruction who underwent myectomy during the same period.

Results: Compared with those with severe obstruction, more patients with latent obstruction were male (63% vs 52%, P < .003), but ages were similar (53 ± 14 years vs 52 ± 15 years). Preoperative symptoms and functional limitation were similar in the 2 groups with 86% and 85%, respectively, having New York Heart Association class III or IV disability. Among patients with latent obstruction, mixed venous oxygen saturation was 61.6% ± 19.0% of predicted compared with 56.8% ± 17.3% for those with severe resting obstruction (P < .008). Septal thickness was less in patients with latent obstruction (20 ± 9 mm vs 22 ± 15 mm, P < .001). Early mortality was 1% in each group, and survival at 5 and 10 years was 93% and 87%, respectively, for patients with latent obstruction compared with 93% and 74%, respectively, for patients with severe resting obstruction preoperatively (P = .34). Self-reported late functional status was similar; 3 to 5 years postoperatively, 81% of patients with latent obstruction preoperatively were in New York Heart Association class I or II compared with 77% of patients with severe resting obstruction.

Conclusions: Patients with obstructive hypertrophic cardiomyopathy who have low resting gradients and latent obstruction may have limiting symptoms comparable to those of patients with more severe resting gradients. Septal myectomy should be offered to these patients because survival and symptom relief are excellent, suggesting that dynamic obstruction is the major hemodynamic problem rather than diastolic dysfunction.

Citing Articles

Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.

Llamas-Esperon G, Berrios-Barcenas E, Cossio-Aranda J, Guerra-Lopez A, Magana-Serrano J, Iturralde-Torres P Arch Cardiol Mex. 2025; 94(Supl 4):1-75.

PMID: 39928711 PMC: 11824882. DOI: 10.24875/ACM.M25000098.


Transapical beating-heart septal myectomy for hypertrophic cardiomyopathy with latent obstruction.

Li J, Wei X Eur J Cardiothorac Surg. 2023; 65(1).

PMID: 38113423 PMC: 10903174. DOI: 10.1093/ejcts/ezad425.


Role of cardiovascular magnetic resonance imaging and cardiopulmonary exercise test in predicting composite clinical outcomes in patients with hypertrophic cardiomyopathy.

Hwang J, Lee S, Kim D, Kim J, Kim E, Chang S PLoS One. 2023; 18(5):e0285887.

PMID: 37192184 PMC: 10187906. DOI: 10.1371/journal.pone.0285887.


Analysis of 3-dimensional interventricular septum and abnormal muscle bundles models for septal myectomy.

Andrushchuk U, Niavyhlas A, Adzintsou V, Haidzel I, Model H, Shket A Interact Cardiovasc Thorac Surg. 2022; 34(1):9-15.

PMID: 34999797 PMC: 8932507. DOI: 10.1093/icvts/ivab213.


Hypertrophic Obstructive Cardiomyopathy.

Batzner A, Schafers H, Borisov K, Seggewiss H Dtsch Arztebl Int. 2019; 116(4):47-53.

PMID: 30855006 PMC: 6415619. DOI: 10.3238/arztebl.2019.0047.